Santoro et al, 1 in their carefully designed and implemented meta-analysis, have concluded that beta-blockers (BB) and renin–angiotensin system inhibitors (RASI), administered after an index episode of Takotsubo syndrome (TTS), are not protective of recurrence. Scrutiny of the ‘limitations’ section of their paper reveals that there are many drawbacks in implementing meta-analyses of existing data from the literature, suggesting that we should resort to large multicentre registries and randomised controlled trials to resolve the conundrum whether such therapy(ies) could prevent TTS recurrence. This author believes that exploration of whether BB and/or RASI could …